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IMPORTANCE Among patients with suspected coronary heart disease (CHD), rates of invasive
angiography are considered too high.
OBJECTIVE To test the hypothesis that among patients with suspected CHD, cardiovascular
magnetic resonance (CMR)–guided care is superior to National Institute for Health and Care
Excellence (NICE) guidelines–directed care andmyocardial perfusion scintigraphy
(MPS)–guided care in reducing unnecessary angiography.
DESIGN, SETTING, AND PARTICIPANTS Multicenter, 3-parallel group, randomized clinical trial
using a pragmatic comparative effectiveness design. From 6 UK hospitals, 1202 symptomatic
patients with suspected CHD and a CHD pretest likelihood of 10% to 90%were recruited.
First randomization was November 23, 2012; last 12-month follow-up wasMarch 12, 2016.
INTERVENTIONS Patients were randomly assigned (240:481:481) to management according
to UK NICE guidelines or to guided care based on the results of CMR or MPS testing.
MAINOUTCOMESANDMEASURES Theprimaryendpointwasprotocol-definedunnecessarycoronary
angiography (normal fractional flow reserve >0.8orquantitative coronary angiography [QCA]
showingnopercentagediameter stenosis70% in 1 viewor50% in2orthogonal views in all
coronary vessels2.5mmdiameter)within 12months. Secondary endpoints includedpositive
angiography,major adverse cardiovascular events (MACEs), andprocedural complications.
RESULTS Among 1202 symptomatic patients (mean age, 56.3 years [SD, 9.0]; women, 564
[46.9%] ;mean CHDpretest likelihood, 49.5% [SD, 23.8%]), number of patients with invasive
coronary angiography after 12monthswas 102 in the NICE guidelines group (42.5% [95%CI,
36.2%-49.0%])], 85 in the CMR group (17.7% [95%CI, 14.4%-21.4%]); and 78 in theMPS
group (16.2% [95%CI, 13.0%-19.8%]). Study-defined unnecessary angiography occurred in
69 (28.8%) in the NICE guidelines group, 36 (7.5%) in the CMR group, and 34 (7.1%) in the
MPS group; adjusted odds ratio of unnecessary angiography: CMR group vs NICE guidelines
group, 0.21 (95%CI, 0.12-0.34, P < .001); CMR group vs theMPS group, 1.27 (95%CI, 0.79-
2.03, P = .32). Positive angiography proportionswere 12.1% (95%CI, 8.2%-16.9%; 29/240
patients) for the NICE guidelines group, 9.8% (95%CI, 7.3%-12.8%; 47/481 patients) for the
CMR group, and 8.7% (95%CI, 6.4%-11.6%; 42/481 patients) for theMPS group. AMACEwas
reported at aminimumof 12months in 1.7%of patients in the NICE guidelines group, 2.5% in
the CMR group, and 2.5% in theMPS group (adjusted hazard ratios: CMR group vs NICE
guidelines group, 1.37 [95%CI, 0.52-3.57]; CMRgroup vsMPSgroup,0.95 [95%CI, 0.46-1.95]).
CONCLUSIONS AND RELEVANCE In patients with suspected angina, investigation by CMR
resulted in a lower probability of unnecessary angiography within 12 months than NICE
guideline–directed care, with no statistically significant difference between CMR andMPS
strategies. There were no statistically significant differences in MACE rates.
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C oronary heart disease (CHD) is a leading cause ofdeath and disability worldwide. Several methods areavailable to diagnose CHD, risk-stratify patients,
and determine the need for revascularization. Myocardial
perfusion scintigraphy (MPS) by single-photon emis-
sion computed tomogra-
phy is themost commonly
used test worldwide for
the assessment of myo-
cardial ischemia, with
robust evidence support-
ing its prognostic value.
However, cardiovascu-
lar magnetic resonance
(CMR) is increasingly
recognized as having high diagnostic accuracy and prognos-
tic value.1,2
Despite the widespread availability and recommenda-
tions for noninvasive imaging in international guidelines,3-5
invasive coronary angiography is commonly used early in
diagnostic pathways in patients with suspected CHD. Evi-
dence from large populations presenting with chest pain has
confirmed that the majority will not have significant
obstructive coronary disease6,7; a large US study reported
that approximately 60% of elective cardiac catheterizations
found no obstructive CHD.8 Thus, avoiding unnecessary
angiography should reduce patient risk and provide signifi-
cant financial savings.
Currentguidelines for investigationof stablechestpainad-
vocatemanagementbasedon thepretest likelihoodofCHD.3-5
However,pretest likelihoodmodelscanoverestimateCHDrisk,
therefore paradoxically increasing the probability of invasive
coronary angiography.9 Todate, there are no large-scale com-
parative effectiveness trials of different functional imaging
strategies recommended by current guidelines.
TheClinical EvaluationofMagneticResonance Imaging in
Coronary Heart Disease 2 (CE-MARC 2) trial was designed to
test thehypothesis that inpatientswith suspectedCHD,CMR-
guided care is superior to national guidelines–directed care4
and MPS-guided care10 in reducing the occurrence of unnec-
essary invasive angiography within 12 months.
Methods
Trial Design
CE-MARC 2 was a multicenter, 3-parallel group, randomized
clinical trial. It used a pragmatic comparative effectiveness
design11 to determine the efficacy and safety of 3 strategies
(CMR-guided care,MPS-guided care [followingAmericanCol-
lege of Cardiology Foundation and American Heart Associa-
tion appropriate use criteria],10 and UK National Institute for
Health andCare Excellence [NICE] guidelines [CG95]4) for in-
vestigating patients with suspected CHD. The studywas con-
ducted inaccordancewith theprotocol (availablewith the sta-
tistical analysis plan inSupplement 1),whichwas approvedby
theUKNationalResearchEthics Service (12/YH/0404) and in-
stitutional review boards of the participating centers. Study
conduct was in accordance with the Declaration of Helsinki;
all patients provided written informed consent.
Trial Population
Patients with suspected angina pectoris were eligible if they
were 30 years or older, had a CHDpretest likelihood of 10% to
90%,4,12 andwere suitable for revascularization.Exclusioncri-
teria included nonanginal chest pain, a normal MPS or car-
diac computed tomography (CCT) result within the previous
2 years, being clinically unstable, previousmyocardial infarc-
tion, previous coronary revascularization, and contraindica-
tion to any study noninvasive imaging test (eTable 4 in
Supplement 2).11 Self-reported race/ethnicity was collected
using Office for National Statistics fixed categories.13
Randomization
Patients were assigned using minimization, incorporating a
random element and 1:2:2 allocation ratio14 through an auto-
mated 24-hour secure-access telephone service by the Clini-
cal Trials Unit. Allocation was to 1 of 5 equally sized groups
(A:B:C:D:E, stratifying on center, age [30-64 years and ≥65
years], CHD pretest likelihood [10%-29%, 30%-60%, 61%-
90%], and sex) following whether management was by NICE
guidelines–directed care (NICE guidelines group; group A)
CMR-guided care (CMR group; groups B or C) or MPS-guided
care (MPS group; groups D or E). Patients randomized to the
NICE guidelines group were scheduled for CCT for patients
with a pretest likelihood of 10% to 29%, MPS for patients
with a pretest likelihood of 30% to 60% or sent directly to
coronary angiography for patients with CHD pretest likeli-
hoods of 61% to 90%.
Diagnostic Testing
All investigationswere performed and interpreted by certified
local physicians using protocols conforming to international
standards.15-18 Quality assurance was undertaken centrally
throughout the trial by blinded, independent, modality-
specific imaging experts (eTable 3 in Supplement 2). Ten
percent of scans for each modality at each recruiting center
Key Points
Question In patients with suspected coronary heart disease, does
a strategy involving cardiovascular magnetic resonance (CMR)
result in less unnecessary angiography than amyocardial perfusion
scintigraphy (MPS) strategy or a national guideline that included
sending high-risk patients directly to angiography?
Findings In this clinical trial, both CMR andMPS strategies
significantly reduced unnecessary angiography rates compared
with national guidelines (7.5% for CMR, 7.1% for MPS, 28.8% for
national guidelines); no statistically significant differences were
seen between CMR andMPS strategies. There was no statistically
significant difference in major cardiovascular event rates at 12
months between the 3 groups.
Meaning Noninvasive functional imaging strategies reduced
unnecessary angiography compared with guidelines-directed care.
CMR cardiovascularmagneticresonance
CCT cardiac computed tomography
FFR fractional flow reserve
MACE major adverse cardiovascular
event
MPS myocardialperfusionscintigraphy
QCA quantitative coronary
angiography
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were centrally reviewed for imagequality and report accuracy.
Detailedprotocols foreach imagingmodalityandcriteria for re-
porting a positive result have been published11; a positive scan
forCMR,MPS,orCCTresultedinprotocol-definedinvasivecoro-
nary angiography and fractional flow reserve (FFR)
measurement.11FFRmeasurement(PressureWire,StJudeMedi-
cal) was performed in all coronary vessels of 2.5mmdiameter
or more with a 40% to 90% stenosis.11 When FFR measure-
ment was not possible for clinical or safety reasons, quantita-
tive coronary angiography (QCA) was performed. All FFR and
QCA results were analyzed at the Glasgow Angiographic Core
Laboratory by a single, independent, blinded observer. Posi-
tive angiography was defined as any lesion with an FFR value
of0.8or less,or, ifFFRmeasurementwasnotperformed,aper-
centage diameter stenosis of 70%or higher in 1 viewor 50%or
higher in 2 orthogonal views.
End Points
Theprimaryendpointwasprotocol-definedunnecessarycoro-
naryangiographyoccurringwithin12months,definedbyanor-
mal FFRvalue (or QCA) in all vessels 2.5mmormore in diam-
eter. By design, this included any unnecessary angiography
occurring after a false-positive test result, patients with high
CHD pretest likelihood sent directly to coronary angiography
(NICE guidelines group only), and imaging results that were
either inconclusive or negative but overruled by the respon-
sible physician.11 Secondary end points included a composite
ofmajor adverse cardiovascular events (MACEs: cardiovascu-
lar death, myocardial infarction, unplanned coronary revas-
cularization, andhospital admission for cardiovascular cause),
and positive angiography rates (recommended by the inde-
pendent data monitoring and ethics committee). Complica-
tions directly related to trial investigations resulting in pro-
longed hospital stay or specific treatment were prespecified
as safety secondary end points. Quality-of-life outcomes and
cost-effectiveness analyses will be reported subsequently.
Trial Oversight
Anindependentdatamonitoringandethicscommitteeandtrial
steering committee assessed study conduct, integrity, and
safety every 6 months (eTable 2 in Supplement 2).
Statistical Analysis
Allowing for 20% noncompletion, 1200 patients would pro-
vide the study with 99% power to detect a difference in un-
necessary angiography between CMR-guided care and NICE
guidelines–directedcare (using2:1 allocation), and94%power
between CMR-guided and MPS-guided care based on pro-
jected unnecessary angiography proportions of 4.5% for the
CMR group, 11.7% for the MPS group, and 30% for the NICE
guidelines group (2-sided, 5% significance for continuity-
corrected χ2 test).19
Logistic regressionswere used tomodel odds of anunnec-
essary angiogram for CMR-guided management vs both
NICE- and MPS-guided management, including stratification
factors (treating centers as fixed effects). Analyses used
intention-to-treat populations and were repeated in per-
protocol populations. Multiple imputation (by fully condi-
tional specification)wasusedformissingbaseline, test, andend
point data to ensure all participants could be included in the
analysis, andavoidtreatingunknownvaluesascertainlyknown
(eg, with mean imputation and no-event imputation).20 Ten
fully imputedanalysisdatasetsweregeneratedbecausethepro-
portionofpatientswithanymissingdatawas less than10%,and
primary endpoint analyses on eachdata setwere combined to
producetheoverall intention-to-treateffectusingRubinrules.21
Theproportionofpatients ineachgroupwithaMACEat 12
months and absolute differences in MACE rates were calcu-
lated. Confidence intervals for proportions and their differ-
enceswerecalculatedbyexactmethods.TimetofirstMACEwas
modeledusingCoxproportional hazards regression, including
stratificationandotherprespecified factors (hypertension,eth-
nicity, smoking, and diabetes) and illustrated using Kaplan-
Meier estimates. CMR and MPS groups were combined into a
single “functional imaging”group tocompareunnecessaryan-
giography vs NICE guidelines–directed care in the 61% to 90%
and 10% to 29% CHD pretest likelihood subgroups. Subgroup
analyses were undertaken by including interaction effects
in regression models. Statistical tests were 2-sided and called
significant at the 5% level. Analyses used SAS (SAS Institute),
version 9.4, after all randomized patients had completed the
12-month follow-up; there were no interim analyses.
Results
Trial Population
Between November 23, 2012, and March 13, 2015, 13 957 pa-
tientswere screened,ofwhom2205wereeligible (Figure 1 lists
reasons for noneligibility and nonconsent). From 6 UK cen-
ters (Leeds, Glasgow, Leicester, Bristol, Oxford, London
[StGeorges]), 1202patients (55%ofeligible)were recruitedand
allocated to NICE guidelines–directed care (n = 240) or man-
agement by CMR (n = 481) or MPS (n = 481) (Figure 1).
Baseline Characteristics
The mean age of patients was 56.3 years (SD, 9.0), 638 pa-
tients (53%) were men, the mean bodymass index (BMI; cal-
culated as weight in kilograms divided by height in meters
squared)was 29.1 (SD, 5.2), and 1107patients (92%)were clas-
sified ethnically as white (Table 1). The study population had
a substantial burden of cardiovascular risk factors: 150 pa-
tients (12.5%) had diabetes, 458 patients (38.1%) had hyper-
tension, 702patients (58.4%)werepast or current tobaccous-
ers, 483 patients (40.2%) had dyslipidemia, and 651 patients
(54.2%) had a family history of premature CHD. Patients had
a median of 2 of these 5 risk factors. All patients were symp-
tomatic,with401patients (33.4%) reporting typical chest pain
and801patients (66.6%) reporting atypical chest pain as their
primary symptom. The assessment of cardiac risk, calculated
according to the 2013 atherosclerotic cardiovascular disease
risk score from the American College of Cardiology Founda-
tionandAmericanHeartAssociationguidelines,22 showedthat
441 of 923patients (47.8%)hada 10-year risk of events of 7.5%
or higher. Themeanpretest likelihood of obstructive CHDac-
cording to the Duke score was 49.5% (SD, 23.8%).12
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Test Conduct
Of 481 patients assigned to the CMR group, 435 patients
(90.4%) had CMR as the initial test (median time from ran-
domization, 20 days [interquartile range, 13-34]), 5 patients
(1.0%) had MPS, 5 patients (1.0%) went directly to angiogra-
phy, and 23 patients (4.8%) had no test. Of 481 patients
Figure 1. Flow of Patients Through the Study of Noninvasive Imaging and Angiography Rates
12 755 Excluded
11 752 Ineligible
308 No reason given
193 Claustrophobia
141 Time or practical reasons
117 Anxiety or needle phobia
132 Other reason
891 Unwilling to take part
63 Missed by research nurse
49 Other
6197 Nonanginal chest pain or CHD
pretest likelihood <10%
583 Prior CABG or PCI
577 Clinician decision
492 Unable to consent
303 Clinically unstable
962 Other ineligibility
1901 CHD pretest likelihood >90%
737 Prior ACS or myocardial infarction
13 957 Patients screened
1202 Randomized
240 Included in intention-to-treat
analysis
481 Included in intention-to-treat
analysis
481 Included in intention-to-treat
analysis
Within 12 months
102 Underwent angiography
14 Underwent PCI
7 Underwent CABG
Within 12 months
85 Underwent angiography
37 Underwent PCI
15 Underwent CABG
Within 12 months
78 Underwent angiography
27 Underwent PCI
13 Underwent CABG
12 months after randomization
234 Completed follow-up
3 Withdrew
3 Died (any cause)
12 months after randomization
467 Completed follow-up
10 Withdrew
4 Died (any cause)
12 months after randomization
468 Completed follow-up
10 Withdrew
3 Died (any cause)
Received trial-specific test
2 Myocardial perfusion scintigraphy
55 Cardiac computed tomography
4 No test
CHD pretest likelihood 10%-29%
82 Myocardial perfusion scintigraphy
1 Cardiac computed tomography
1 Dobutamine stress echo
1 Immediate angiography
3 No test
CHD pretest likelihood 30%-60%
1 Cardiovascular magnetic resonance
2 Myocardial perfusion scintigraphy
84 Immediate angiography
4 No test
CHD pretest likelihood  61%-90%
Received trial-specific testa
435 Cardiovascular magnetic resonance
5 Myocardial perfusion scintigraphy
2 Cardiac computed tomography
15 Exercise treadmill test or dobutamine
stress echo
5 Immediate angiography
23 No test
Received trial-specific testa
4 Cardiovascular magnetic resonance
446 Myocardial perfusion scintigraphy
1 Cardiac computed tomography
5 Exercise treadmill test or dobutamine
stress echo
5 Immediate angiography
21 No test
240 Randomized to receive NICE
guidelines–based management
200 Received initial randomized
test and per-protocol
compliance with test result
481 Randomized to receive cardiovascular
magnetic resonance-guided care
414 Received initial randomized
test and per-protocol
compliance with test result
481 Randomized to receive myocardial
perfusion scintigraphy-guided care
368 Received initial randomized
test and per-protocol
compliance with test result
ACS indicates acute coronary syndrome; CABG, coronary artery bypass grafting;
CHD, coronary heart disease; NICE, National Institute for Health and Care
Excellence; PCI, percutaneous coronary intervention.
a Patients may have receivedmore than 1 test, in addition to or as an alternative
to their strategy.
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assigned to the MPS group, 446 patients (92.7%) had MPS as
the initial test (median time from randomization, 28 days
[interquartile range, 22-39]), 4 patients (0.8%) had CMR, 5
patients (1.0%) went directly to angiography, and 21 patients
(4.4%) had no test. Of 240 patients assigned to the NICE
guidelines group, 56 patients (23.3%) had CCT (median time
from randomization, 34 days [interquartile range, 14-44]),
86 patients (35.8%) had MPS, 85 patients (35.4%) went
directly to angiography, and 11 patients (4.6%) had no test.
The numbers of patients adherent to receiving both their
initial randomized test and per-protocol compliance with
their test result were 200 patients (83.3%) in the NICE
guidelines group, 414 patients (86.1%) in the CMR group,
and 368 patients (76.5%) in the MPS group.
Study sites reported their interpretation of the initial test
as positive for CHD in 54 of 435 patients (12.4%) in the CMR
group, in 81 of 446 patients (18.2%) in the MPS group, and in
19 of 142 patients (13.4%) in theNICE guidelines group. There
was no difference in revascularization rates (Figure 1) be-
tween the 3 groups (P = .47). The rate of patientswith incom-
plete data required for analysis of the primary end point was
low: 18 of 240 patients (7.5%) in the NICE guidelines group,
50 of 481 patients (10.4%) in theCMRgroup, and 33 of 481 pa-
tients (6.9%) in the MPS group. Of these, 11 of 240 patients
(4.6%) in theNICE guidelines group, 23 of 481 patients (4.8%)
in the CMR group, and 21 of 481 patients (4.4%) in the MPS
group were related to missing test results.
Primary End Point
Overall, 265patients (22.0%)underwentat least 1 coronaryan-
giogram (10 patients underwent 2 angiograms) within 12
months of randomization: 102 of 240 patients (42.5%) in the
NICE guidelines group, 85 of 481 patients (17.7%) in the CMR
group, and 78 of 481 patients (16.2%) in the MPS group. The
primary endpoint of unnecessary angiographyoccurred in69
patients (28.8%) in the NICE guidelines group, 36 patients
(7.5%) in the CMR group, and 34 patients (7.1%) in the MPS
group.Of these angiograms, 98angiograms (70.5%)hadnovi-
sual stenosis and were not assessed further, 40 angiograms
(28.8%) reached theconclusionbyFFRmeasurementand1an-
giogram (0.7%) involvedQCAonly. The adjusted odds ratio of
unnecessary angiography for the CMR group vs the NICE
Table 1. Baseline Characteristics of PatientsWith Suspected Coronary Heart Disease (CHD) by Study Group
Characteristic
Total Patients,
No. (%)
(N = 1202)
Guided Care, No. (%)
NICE
(n = 240)
CMR
(n = 481)
MPS
(n = 481)
Age, mean (SD), y 56.3 (9.03) 56.5 (9.21) 56.5 (9.10) 55.9 (8.87)
Women 564 (46.9) 112 (46.7) 227 (47.2) 225 (46.8)
Nonwhite race/ethnicity 95 (7.9) 19 (7.9) 38 (7.9) 38 (7.9)
Cardiac risk factors
BMI, mean (SD) 29.1 (5.23) 29.0 (5.24) 29.2 (5.36) 29.1 (5.12)
Hypertension 458 (38.1) 99 (41.3) 177 (36.8) 182 (37.8)
Diabetes 150 (12.5) 24 (10.0) 53 (11.0) 73 (15.2)
Dyslipidemia 483 (40.2) 99 (41.3) 186 (38.7) 198 (41.2)
Former or current smoker 702 (58.4) 147 (61.3) 284 (59.0) 271 (56.3)
Family history of premature CHDa 651 (54.2) 140 (58.3) 252 (52.4) 259 (53.8)
Peripheral vascular disease 27 (2.2) 10 (4.2) 8 (1.7) 9 (1.9)
Cerebrovascular disease 42 (3.5) 8 (3.3) 17 (3.5) 17 (3.5)
Nature of angina
Atypical 801 (66.6) 158 (65.8) 318 (66.1) 325 (67.6)
Typical 401 (33.4) 82 (34.2) 163 (33.9) 156 (32.4)
Medications
Antiplatelet therapy 689 (57.3) 150 (62.5) 271 (56.3) 268 (55.7)
β-Blocker 381 (31.7) 74 (30.8) 150 (31.2) 157 (32.6)
Statin or other lipid-lowering therapy 500 (41.6) 108 (45.0) 191 (39.7) 201 (41.8)
Angiotensin-converting enzyme inhibitor
or angiotensin II receptor blocker
303 (25.2) 66 (27.5) 115 (23.9) 122 (25.4)
Other antianginal medication 701 (58.3) 142 (59.2) 283 (58.8) 276 (57.4)
Risk Burden
Pretest likelihood, %b
Mean (SD), % 49.5 (23.78) 50.7 (23.28) 49.9 (24.25) 48.6 (23.57)
10-29c 314 (26.1) 61 (25.4) 128 (26.6) 125 (26.0)
30-60c 450 (37.4) 88 (36.7) 179 (37.2) 183 (38.0)
61-90c 438 (36.4) 91 (37.9) 174 (36.2) 173 (36.0)
No. of risk factors per patient, mean (SD) 2.0 (1.13) 2.1 (1.05) 2.0 (1.18) 2.0 (1.11)
10-y ASCVD risk ≥7.5%,
No./total patients (%)d
441/923 (47.8) 93/179 (52.0) 175/377 (46.4) 173/367 (47.1)
Abbreviations: ACE,
angiotensin-converting enzyme;
ARB, angiotensin II receptor blocker;
ASCVD, atherosclerotic
cardiovascular disease; BMI, body
mass index (calculated as
weight in kilograms divided
by height in meters squared);
CMR, cardiovascular magnetic
resonance; MPS, myocardial
perfusion scintigraphy;
NICE, National Institute for Health
and Care Excellence.
a Family history of premature CHD
defined as diagnosis of the disease
in a male first-degree relative before
aged 55 years or in a female
first-degree relative aged 65 years.
bAccording to Pryor et al.12
c Categories used to decide
stratification in the NICE
guidelines group.
dAccording to eligibility criteria
of Goff et al.22
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guidelinesgroupwas0.21 (95%CI,0.12-0.34;P < .001)and1.27
(95% CI, 0.79-2.03; P = .32) for the CMR group vs the MPS
group. Table 2 shows individual components of the primary
endpoint. For both comparisons, theprimary analysiswas re-
peated in the per-protocol population, with no effect on the
trial results. Sensitivity analyses using random center effects
or adjusting for further risk factors (hypertension, ethnicity,
smoking status) or using the per-protocol population did not
changeoverall trial conclusions (eTable5 inSupplement2).Ex-
ploratory subgroupanalyses showedconsistent results across
subgroups (Figure 2).
Secondary End Points
Positive angiography was observed in 29 patients (12.1%
[95% CI, 8.2%-16.9%]) in the NICE guidelines group, 47
patients (9.8% [95% CI, 7.3%-12.8%]) in the CMR group, and
42 patients (8.7% [95% CI, 6.4%-11.6%) in the MPS group
(P = .36). During the minimum 1-year follow-up (median,
15.8 months [interquartile range, 12.1-24.2]), 36 patients
(3.0%) had at least 1 MACE: NICE guidelines group, 6
patients (2.5%); CMR group, 15 patients (3.1%); MPS group,
15 patients (3.1%) (Table 2). Annualized MACE rates were
1.6% for the NICE guidelines group, 2.0% for the CMR
group, and 2.0% for the MPS group. Adjusted hazard ratios
for MACE were 1.37 (95% CI, 0.52-3.57; P = .52) for the CMR
group vs the NICE guidelines group and 0.95 (95% CI, 0.46-
1.95; P = .88) for the CMR group vs the MPS group. Hard
events (cardiovascular death and myocardial infarction)
occurred in 3 patients (1.3%) in the NICE guidelines group, 5
patients (1.0%) in the CMR group, and 4 patients (0.8%) in
Table 2. Summary of Trial End Points for PatientsWith Suspected Coronary Heart Disease, by Each Guided Care Group
Total Patients
(N = 1202)
Guided Care Absolute Differences, % (95% CI)
NICE Guidelines
(n = 240)
CMR
(n = 481)
MPS
(n = 481) CMR vs NICE CMR vs MPS
Primary End Point
Unnecessary invasive angiography,
No. of patients (%)
139 (11.6) 69 (28.8) 36 (7.5) 34 (7.1) −21.3
(−28.7 to −13.6)
0.4
(−6.0 to 6.8)
Components of the primary
end point
False-positive
noninvasive test
35 5 18 12
Direct to angiography
(by strategy)
59 59
Negative noninvasive test,
not per-protocol
41 5 15 21
Inconclusive noninvasive test
or result
4 3 1
Secondary End Points
Positive angiography occurrence,
No. of patients (%)
118 (9.8) 29 (12.1) 47 (9.8) 42 (8.7) −2.3
(−10.0 to 5.4)
1.0
(−5.4 to 7.5)
True-positive noninvasive test 73 4 38 31
Direct to angiography
(by strategy)
23 23
Negative noninvasive test,
not per-protocol
9 1 2 6
Inconclusive noninvasive test
or result
2 2
Acute or urgent angiography
indication
9 1 4 4
Angiography as alternative initial
investigation
2 1 1
Major adverse cardiovascular
events, No. of events
(No. of patients)
44 (36) 7 (6) 20 (15) 17 (15) 1.0
(−6.7 to 8.8)
0.0
(−6.4 to 6.4)
Cardiovascular death 5 1a 1 3
Myocardial infarction 9 2 5 2
Revascularization
Unplanned PCI 12 2 6 4
Unplanned CABG 1 1
Arrhythmia 9 2 4 3
Heart failure 4 4
Stroke or TIA 4 3 1
Abbreviations: CABG, coronary artery bypass graft; CMR, cardiovascular
magnetic resonance; MACE, major adverse cardiovascular events;
MPS, myocardial perfusion scintigraphy; NICE, National Institute for Health
and Care Excellence; PCI, percutaneous coronary intervention; TIA, transient
ischemic attack.
a This event occurred 2 days after the 3-year cutoff, so is excluded from
summaries of absolute MACE rates at 3 years. All other events occurred within
3 years of randomization. Three-year MACE rates include all participants
(median follow-up, 16months).
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Figure 2. Effect of Specific Patient Characteristics on Results for CMR-Guided Care vs NICE Guidelines-Directed Care andMPS-Guided Care
Among PatientsWith Suspected Coronary Heart Disease
Cardiovascular magnetic resonance vs NICE guidelinesA
Unnecessary
Angiography
Less Likely
For CMR
Unnecessary
Angiography
More Likely
For CMR
0.01 101.00.1
Adjusted Odds Ratio (95% CI)
Subgroup
Sex
Adjusted Odds
Ratio of Unnecessary
Angiography Within
12 mo (95% CI)
25415 12841Men 0.14 (0.07-0.28)
22721 11228Women 0.31 (0.15-0.61)
Age group, y
38926 1924430-64 0.28 (0.15-0.49)
9210 4825≥65 0.09 (0.03-0.22)
Race/ethnicity (white vs nonwhite)
44331 22163White 0.19 (0.11-0.33)
385 196Asian, black, other, or not stated 0.37 (0.09-1.42)
Hypertension
17713 9928Yes 0.22 (0.10-0.45)
30423 14141No 0.19 (0.10-0.37)
Smoking Status
19715 9325Never smoked 0.21 (0.10-0.45)
28421 14744Former or current smoker 0.20 (0.11-0.37)
Diabetes
42832 21658No diabetes 0.22 (0.13-0.38)
534 2411Type I or type II 0.11 (0.03-0.39)
Known family history of CHD
22919 10031No or not known 0.22 (0.11-0.44)
25217 14038Yes 0.19 (0.10-0.37)
BMI
1017 52160-25 0.15 (0.06-0.39)
19618 1013526-30 0.18 (0.09-0.38)
18411 8718>30 0.30 (0.13-0.68)
48136 24069Overall 0.21 (0.12-0.34)
Cardiovascular magnetic resonance vs myocardial perfusion scintigraphyB
Unnecessary
Angiography
Less Likely
For CMR
Unnecessary
Angiography
More Likely
For CMR
0.01 101.00.1
Adjusted Odds Ratio (95% CI)
Subgroup
Sex
Adjusted Odds
Ratio of Unnecessary
Angiography Within
12 mo (95% CI)
25415 15 256Men 1.23 (0.60-2.52)
22721 19 225Women 1.30 (0.68-2.49)
Age group, y
38926 26 38830-64 1.18 (0.69-2.01)
9210 8 93≥65 1.61 (0.60-4.36)
Race/ethnicity (white vs nonwhite)
44331 31 443White 1.18 (0.72-1.95)
385 3 38Asian, black, other, or not stated 2.21 (0.50-9.74)
Hypertension
17713 11 182Yes 1.57 (0.73-3.39)
30423 23 299No 1.11 (0.61-2.02)
Smoking Status
19715 15 210Never smoked 1.19 (0.58-2.43)
28421 19 271Former or current smoker 1.33 (0.72-2.48)
Diabetes
42832 25 408No diabetes 1.43 (0.84-2.44)
534 9 73Type I or type II 0.86 (0.28-2.67)
Known family history of CHD
22919 19 222No or not known 1.26 (0.67-2.38)
25217 15 259Yes 1.30 (0.65-2.61)
BMI
1017 7 1030-25 1.35 (0.46-3.92)
19618 14 19726-30 1.40 (0.68-2.89)
18411 13 181>30 1.09 (0.50-2.35)
48136 34 481Overall 1.27 (0.79-2.03)
Cardiovascular Magnetic
Resonance
Unnecessary
Angiography, No.
Participants,
No.
NICE Guidelines
Unnecessary
Angiography, No.
Participants,
No.
Cardiovascular Magnetic
Resonance
Unnecessary
Angiography, No.
Participants,
No.
Myocardial Perfusion
Scintigraphy
Unnecessary
Angiography, No.
Participants,
No.
CMR indicates cardiovascular magnetic resonance; ITT, intention to treat; NICE,
National Institute for Health and Care Excellence; MPS, myocardial perfusion
scintigraphy. Variables in the adjusted analysis for odds ratios included
hypertension, ethnicity, and smoking status.
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the MPS group (P = .93). Figure 3 shows the Kaplan-Meier
cumulative incidence estimate of first MACE. In the study,
5 test-related medical complications were reported: CMR
(1 case: mild urticarial reaction), MPS (0 cases), CCT (1 case:
vasovagal episode), and angiography (3 cases: ventricular
tachycardia, pseudo-aneurysm and popliteal deep venous
thrombosis, right coronary artery spasm and transient ST
elevation).
Functional Imaging Assessment
Using functional imaging as a first-line strategy (CMRorMPS)
inpatientswith a61% to90%(high; n = 389)CHDpretest like-
lihood resulted in substantially reduced odds of unnecessary
angiography comparedwith theNICE guidelines group; 29 of
307 patients (9.4%) for functional imaging groups vs 51 of 82
patients (62.2%) for theNICEguidelinesgroup,odds ratio (OR)
0.048 (95% CI, 0.02-0.10), P < .001. Among those with less
than 30% (low; n = 330) CHD pretest likelihood, the odds of
unnecessary angiography were also numerically lower by a
functional imagingapproachcomparedwithanatomical (CCT)
assessment (13 of 269patients (4.8%) for funtional imagingvs
7 of 61 patients (11.5%) for anatomical assessment; OR, 0.44
[95% CI, 0.17-1.17]; P = .099).
Discussion
CE-MARC 2 was a multicenter, randomized clinical trial in a
large community-based population of symptomatic patients
undergoing assessment for suspected CHD, in whom further
investigation was appropriate according to international
guidelines. A CMR-guided strategy significantly reduced
unnecessary angiography occurrence compared with NICE
guidelines-guided care, but was not significantly different
from an MPS-guided strategy (following US appropriate use
criteria).10 Between the 3 strategies, there was no difference
in MACE rates at 12 months or disease detection (positive
angiography) rates.
There is concern that coronary angiography is overused in
the diagnostic pathway of suspectedCHDand that themajor-
ity of patients investigated will not have significant obstruc-
tive coronary disease.6,7 Avoiding unnecessary invasive angi-
ography could have significant financial benefits, avoids
exposing patients to unnecessary risk, and is also a strong pa-
tient desire.23 For this reason, this outcomewas chosen as the
patient-focused primary end point.
Current international guidelines for investigation and
management of suspected CHD all suggest risk stratification
based on pretest likelihood estimation.12,24,25 The Duke
score, used in NICE guidelines, is based upon the original
Diamond Forrester model, but includes additional demo-
graphic factors to further stratify risk.12 These models,
derived more than 3 decades ago, tend to overestimate CHD
risk because patient demographics, risk factors, and treat-
ment have changed considerably over time.26 In the
CE-MARC 2 trial, the reduction in unnecessary angiography
by a CMR or MPS strategy appears largely driven by the
overestimation of disease probability from using the Duke
score. Current NICE guidelines categorize a pretest likeli-
hood of 60% to 90% as being at high-risk of CHD, and rec-
ommend direct referral for angiography. In the CE-MARC 2
trial, this explained the majority of patients in the NICE-
guidelines group who got referred for angiography (82 of
102 patients; 80.4%), and the majority of unnecessary
angiograms (59 of 69 patients; 85.5%). This was further
emphasized by the preplanned, subanalysis of any func-
tional imaging (CMR or MPS) in the 60% to 90% (high risk)
pretest likelihood population, which showed substantially
reduced odds of unnecessary angiography in this combined
subgroup compared with the NICE guideline group.
Overall, rates of disease detection (positive angiogra-
phy) were comparable for the 3 strategies, suggesting no
penalty for using functional imaging as a gatekeeper for
angiography, even in high-risk subgroups. Consistent with
published studies, the CE-MARC 2 trial showed a low overall
rate of MACE in a stable chest pain population, with no early
difference between strategies.
It remains a point of debate as to whether all of protocol-
defined unnecessary angiograms in this studywere clinically
unnecessary; some would argue that negative tests are the
“price topay” fornotmissing importantdisease inothers. This
assumes a population perspective, and our trial primary end
pointwasderivedaftercloseconsultationwithpatientandpub-
lic representatives: froman individual patient perspective, an
angiogram that does not change their treatment or their clini-
cal outcome is considered by patients to have been unneces-
sary. Guidelines are clear that physicians do not need to un-
Figure 3. Time to First Major Adverse Cardiovascular Event After
aMinimumof 12-Month Follow-up FromRandomization Among Patients
With Suspected Coronary Heart Disease (Median, 16Months)
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test P values) were calculated by Cox proportional hazards modeling, adjusted
for randomizing center, age category, sex, coronary heart disease pretest
likelihood category, hypertension, race/ethnicity, diabetes, and smoking status.
Themedianmonths of follow-up for the NICE guidelines group was 19.9months
(interquartile range [IQR], 12.1-24.1), 15.3 months (IQR, 12.2-24.2) for the CMR
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dertakeangiography toeitherdiagnoseanginaorofferprimary
prevention and symptom control.
To our knowledge, there have been no randomized clini-
cal trials comparing the performance of current management
guidelines and a broad functional imaging approach in terms
of important clinical end points. Although cross-sectional
imaging (CMR and CCT) has improved diagnostic ability, ben-
efits in terms of health outcomes aremore difficult to demon-
strate, partly due to complexity of subsequent treatment ef-
fects. Functional vs anatomical assessment as a potential
gatekeeper to the catheterization laboratory is a topic of on-
going debate.27,28 The ProspectiveMulticenter Imaging Study
for Evaluation of Chest Pain (PROMISE) trial showed no im-
provement in clinical outcomesusingCCTvsavarietyof func-
tional tests inpatients investigatedforsuspectedCHD;whereas
the CCT strategy increased rates of cardiac catheterization
(12.2%forCCTvs8.1%for avarietyof functional tests,P = .02)
and 90 day coronary revascularization (6.2% for CCT vs 3.2%
for a variety of functional tests, P < .001).27 This may be im-
portant following a recent observational study of 544 US cen-
ters showinghigher ratesof inappropriatepercutaneous coro-
nary intervention at sites performing the highest rates of
angiography, suggesting anatomical assessment couldpredis-
posepatients tounnecessary therapy.29Althoughnumbersare
small, in theCE-MARC2 trial an increased rate of unnecessary
angiographywassuggestedinthelow-risksubgroupoftheNICE
guidelines group, the majority of whom underwent CCT.
Limitations
This study has several important limitations. First, the false-
positive and false-negative rates are often quantities of inter-
est inevaluatingdiagnosticmethods.TheCE-MARC2trialonly
angiographically verified a subset of patients, contingent on
strategy findings, and so cannot provide accurate estimates.
TheoriginalCE-MARCtrialdefined the false-positiveandfalse-
negative rates for CMR and MPS, and showed CMR-guided
strategy as being superior to theMPS-guided strategy.1 In the
current study, therewas no statistical difference between the
CMRandMPS strategies for reduction inunnecessary angiog-
raphy, despite the finding from the CE-MARC trial. However,
the CE-MARC trial was able to detect small differences due to
its paireddesign (all patientsunderwent all tests),whereas the
current study compared independent groups, which confers
lower power.
Second, the study population was predominantly white
northern European, therefore findings may not translate to
other populations; geographic heterogeneity of CHD inci-
dence is well known.25
Third, at trial initiation, contemporaryguidelinesused the
Duke score,3,4 with the NICE guidelines classifying high risk
for CHD as 60% to 90% pretest likelihood. It is now recog-
nized that this may overestimate CHD risk, such that recent
guidelines5 have adopted a recalibrated risk model.25
Fourth, the primary end point was objective (using FFR
measurement), although performancewas not clinically pos-
sible in all cases; blinded core laboratory analysis of QCAdata
avoided subjective visual angiography interpretation.
Fifth, overall full adherence to theprotocolwashigh,with
some unavoidable variation due to individual clinical prac-
tice,which couldhave introducedbias (eg, abnormal imaging
resultsnotproceeding toangiography).Tomitigate this, analy-
sis was by intention-to-treat principles and the primary end
point was purposely all inclusive (ie, false-positives, true-
negatives when not believed by clinicians, and also test fail-
ures). The slightly different rates of incomplete data (not sta-
tistically significant)betweenstudygroupswasnotof concern,
as the data completeness rate was high overall. Per-protocol
and sensitivity analyses (eTable 5 in Supplement 2) didnot al-
ter the trial conclusions.
Sixth, although clinically robust, a MACE is not a proxy
for a missed diagnosis or treatment (eg, missed opportunity
for revascularization by not having angiography [due to a
false-negative result]). However, it remains debatable
whether revascularization for stable angina has prognostic
benefit over optimal medical therapy, which will be
answered by the ongoing International Study of Compara-
tive Health Effectiveness With Medical and Invasive
Approaches (ISCHEMIA) trial.30
Seventh,qualityof life andcost-effectivenessanalyseswill
be important forunderstanding thepatient-centeredperspec-
tivesandpayer/policy implicationsof these findings; thesedata
are currently being collected and analyzed.
Conclusions
In patients with suspected angina, investigation by CMR re-
sulted ina lowerprobabilityofunnecessaryangiographywithin
12 months than NICE guideline–directed care, with no statis-
tically significant difference between CMR and MPS strate-
gies.Therewerenostatistically significantdifferences inMACE
rates at 12 months after randomization.
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